Armata Pharmaceuticals, Inc. 8-K

Summary

FDA QIDP designation for AP-SA02, Armata’s intravenous phage candidate for adjunct treatment of complicated bacteremia caused by MSSA or MRSA. The designation makes AP-SA02 eligible for an additional five years of market exclusivity and for Fast Track status, which can include priority and rolling review; Armata plans to request Fast Track designation.

Key Figures

• The Phase 1b/2a development of AP-SA02 was partially supported by a $26.2M Department of Defense award. Armata reported positive Phase 2a results in October 2025.

Investor Takeaways

• Armata anticipates initiating a Phase 3 superiority study for complicated S. aureus bacteremia in H2 2026; initiation and trial progress are the next milestones to watch.
• FDA action on Armata’s planned Fast Track request will determine whether AP-SA02 receives that additional development and review pathway.